drugset
drugset / Trial / NCT04532957

A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects

NCT04532957 ↗

Phase 1 Completed 24 enrolled KBP Biosciences Covance · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a double-blind, placebo-controlled, multiple oral dose study to evaluate safety, tolerability, and pharmacokinetic of KBP-7072 in healthy subjects.

Timeline

Start
2020-08-11
Primary completion
2020-10-08
Completion
2020-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject KBP-7072 Small molecule 100 mg Oral
Subject KBP-7072 Small molecule 150 mg Oral
Subject KBP-7072 Small molecule 200 mg Oral

Indications

No indication recorded.